Hims & Hers (NYSE:HIMS) fell ~8% in the premarket Thursday after a federal judge denied a motion filed by a compounding trade group over the FDA’s decision to declare that Eli Lilly’s (NYSE:LLY) ...
Zacks Investment Research on MSN
Hims & Hers Expands Care Scope as Prescription Platforms Evolve
The renowned health and wellness platform, Hims & Hers Health, Inc.’s HIMS, business model links virtual consultations ...
What To Know: While Hims & Hers doesn’t manufacture the GLP-1 drugs, a class of medications that help manage Type 2 diabetes and obesity, like Eli Lilly’s Zepbound and Novo Nordisk’s Ozempic, it sells ...
Shares of Hims & Hers are trending Thursday morning. The San Francisco-based telehealth company announced an international ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback